EE05332B1 - 3-{(3R,4R)-4-metl-3-[metl(7H-prrolo[2,3-d]primidiin-4-l)amino]piperidiin-1 -l}-3-oksopropionitriil, selle farmatseutiliselt vastuv?etav sool ja nende kasutamine - Google Patents

3-{(3R,4R)-4-metl-3-[metl(7H-prrolo[2,3-d]primidiin-4-l)amino]piperidiin-1 -l}-3-oksopropionitriil, selle farmatseutiliselt vastuv?etav sool ja nende kasutamine

Info

Publication number
EE05332B1
EE05332B1 EEP200300594A EEP200300594A EE05332B1 EE 05332 B1 EE05332 B1 EE 05332B1 EE P200300594 A EEP200300594 A EE P200300594A EE P200300594 A EEP200300594 A EE P200300594A EE 05332 B1 EE05332 B1 EE 05332B1
Authority
EE
Estonia
Prior art keywords
methyl
oxopropionitrile
pyrrolo
pyrimidin
piperidine
Prior art date
Application number
EEP200300594A
Other languages
English (en)
Estonian (et)
Inventor
Ernest Wilcox Glenn
Koecher Christian
Vries Ton
Edward Flanagan Mark
John Munchhof Michael
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05332(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200300594A publication Critical patent/EE200300594A/xx
Publication of EE05332B1 publication Critical patent/EE05332B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300594A 2001-05-31 2002-05-29 3-{(3R,4R)-4-metl-3-[metl(7H-prrolo[2,3-d]primidiin-4-l)amino]piperidiin-1 -l}-3-oksopropionitriil, selle farmatseutiliselt vastuv?etav sool ja nende kasutamine EE05332B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29477501P 2001-05-31 2001-05-31
US34104801P 2001-12-06 2001-12-06
PCT/IB2002/001905 WO2002096909A1 (en) 2001-05-31 2002-05-29 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors

Publications (2)

Publication Number Publication Date
EE200300594A EE200300594A (et) 2004-04-15
EE05332B1 true EE05332B1 (et) 2010-08-16

Family

ID=26968730

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300594A EE05332B1 (et) 2001-05-31 2002-05-29 3-{(3R,4R)-4-metl-3-[metl(7H-prrolo[2,3-d]primidiin-4-l)amino]piperidiin-1 -l}-3-oksopropionitriil, selle farmatseutiliselt vastuv?etav sool ja nende kasutamine

Country Status (52)

Country Link
US (2) US7301023B2 (cs)
EP (3) EP1666481B9 (cs)
JP (1) JP4381137B2 (cs)
KR (5) KR20060133117A (cs)
CN (1) CN1729192A (cs)
AP (1) AP1859A (cs)
AR (2) AR037321A1 (cs)
AT (1) ATE519741T1 (cs)
AU (2) AU2002304401C1 (cs)
BE (1) BE2017C032I2 (cs)
BG (1) BG66489B1 (cs)
BR (1) BR0209246A (cs)
CA (1) CA2448281C (cs)
CL (1) CL2008000762A1 (cs)
CR (1) CR10177A (cs)
CU (1) CU23337B7 (cs)
CY (2) CY1113322T1 (cs)
CZ (1) CZ304366B6 (cs)
DK (1) DK1666481T3 (cs)
EA (2) EA012666B1 (cs)
EC (1) ECSP034865A (cs)
EE (1) EE05332B1 (cs)
ES (2) ES2369226T3 (cs)
FR (1) FR17C1031I2 (cs)
GE (1) GEP20063784B (cs)
GT (2) GT200200100A (cs)
HR (1) HRP20030943B1 (cs)
HU (2) HU230876B1 (cs)
IL (1) IL158588A0 (cs)
IS (1) IS3023B (cs)
LT (1) LTC1666481I2 (cs)
LU (1) LUC00031I2 (cs)
MA (1) MA27029A1 (cs)
MX (1) MXPA03011062A (cs)
MY (1) MY129649A (cs)
NL (1) NL300887I2 (cs)
NO (3) NO328578B1 (cs)
NZ (2) NZ530380A (cs)
OA (1) OA12612A (cs)
PA (1) PA8546301A1 (cs)
PE (1) PE20030561A1 (cs)
PL (2) PL367945A1 (cs)
PT (1) PT1666481E (cs)
RS (1) RS52144B (cs)
SI (1) SI1666481T1 (cs)
SK (2) SK288199B6 (cs)
TN (1) TNSN03128A1 (cs)
TW (2) TWI316061B (cs)
UA (1) UA80093C2 (cs)
UY (1) UY27317A1 (cs)
WO (1) WO2002096909A1 (cs)
ZA (1) ZA200307982B (cs)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EE05351B1 (et) 1999-12-10 2010-10-15 Pfizer Products Inc. Prrolo[2,3-d]primidiinhendid
ATE323704T1 (de) * 2000-06-26 2006-05-15 Pfizer Prod Inc Pyrrolo¬2,3-däpyrimidin verbindungen als immunosuppressive wirkstoffe
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7476683B2 (en) * 2002-08-27 2009-01-13 Merck Patent Gmbh Glycinamide derivatives as raf-kinase inhibitors
CA2507392A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Method of treatment of transplant rejection
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
EP1755680A1 (en) * 2004-05-03 2007-02-28 Novartis AG Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
CA2572314A1 (en) 2004-06-29 2006-01-12 Christopher N. Farthing Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity
TW200615268A (en) 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
WO2006056399A2 (en) * 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
ES2651349T3 (es) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta JAK
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
ES2377771T3 (es) 2005-07-29 2012-03-30 Pfizer Products Inc. Derivados de pirrolo [2,3-d]pirimidina, sus intermedios y síntesis
US20070149506A1 (en) 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
PL2343299T3 (pl) 2005-12-13 2016-09-30 Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
JP5492565B2 (ja) 2006-12-22 2014-05-14 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2714092T3 (es) 2007-06-13 2019-05-27 Incyte Holdings Corp Uso de sales del inhibidor de quinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
EP2175858B1 (en) * 2007-07-11 2014-09-10 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
KR101700454B1 (ko) 2008-02-15 2017-01-26 리겔 파마슈티칼스, 인크. 피리미딘-2-아민 화합물 및 ｊａｋ 키나제 억제제로서의 그의 용도
RS55263B1 (sr) 2008-03-11 2017-02-28 Incyte Holdings Corp Derivati azetidina i ciklobutana kao jak inhibitori
PT2323993E (pt) 2008-04-16 2015-10-12 Portola Pharm Inc 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2009131687A2 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US20110165183A1 (en) * 2008-08-01 2011-07-07 Biocryst Pharmaceuticals, Inc. Piperidine derivatives as jak3 inhibitors
HRP20140395T1 (hr) 2008-08-20 2014-06-06 Zoetis Llc SPOJEVI PIROLO[2,3-d]PIRIMIDINA
CA2752150A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
CA2759026C (en) * 2009-04-20 2019-01-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
ME03556B (me) 2009-05-22 2020-07-20 Incyte Holdings Corp 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1 h-pirazol-1-il]oktan- ili нертan - niтril kао јак inhibiтori
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
RU2538204C2 (ru) * 2009-09-10 2015-01-10 Ф.Хоффманн-Ля Рош Аг Ингибиторы jak
CA2777114C (en) 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
PH12012500583A1 (en) 2009-10-15 2012-10-22 Pfizer Pyrrolo[2,3-d] pyrimidine compounds
JP5739446B2 (ja) 2009-12-18 2015-06-24 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
CA2781578A1 (en) * 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
JP2013518882A (ja) 2010-02-05 2013-05-23 ファイザー・インク ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物
RS54823B1 (sr) 2010-03-10 2016-10-31 Incyte Holdings Corp Derivati piperidin-4-il azetidina kao inhibitori jak1
MX338228B (es) 2010-05-21 2016-04-08 Incyte Corp Formulacion topica para inhibidor de cinasas janus (jak).
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
NZ611151A (en) 2010-11-19 2015-06-26 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
EA026317B1 (ru) 2011-02-18 2017-03-31 Новартис Фарма Аг КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ mTOR/JAK
EP2691395B1 (en) 2011-03-28 2017-08-30 ratiopharm GmbH Processes for preparing tofacitinib salts
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
SG193245A1 (en) * 2011-04-08 2013-10-30 Pfizer Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
EP2524688B1 (en) 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
PH12013502612A1 (en) 2011-06-20 2014-04-28 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
HK1198579A1 (en) 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
SG11201402570QA (en) 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP2785184B1 (en) 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
WO2013090490A1 (en) 2011-12-15 2013-06-20 Ratiopharm Gmbh Tofacitinib salts
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
CN104837817B (zh) 2012-07-25 2017-03-22 力奇制药公司 制备3‑氨基‑哌啶化合物的合成路线
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
TW201922255A (zh) 2012-11-15 2019-06-16 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
CN104955803B (zh) * 2012-11-30 2017-11-28 斯洛文尼亚莱柯制药股份有限公司 通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
US9481679B2 (en) 2012-12-17 2016-11-01 Sun Pharmaceutical Industries Limited Process for the preparation of tofacitinib and intermediates thereof
EP2938616A4 (en) 2012-12-28 2016-06-15 Glenmark Pharmaceuticals Ltd PROCESSING METHOD FOR THE PRODUCTION OF TOFACITINIB AND INTERMEDIATE PRODUCTS THEREOF
LT2958921T (lt) 2013-02-22 2017-11-27 Pfizer Inc. Pirolo[2, 3 -d]pirimidino dariniai, kaip janus kinazės (jak) inhibitoriai
TWI634121B (zh) 2013-03-06 2018-09-01 英塞特控股公司 用於製備ｊａｋ抑制劑之方法及中間物
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
CN104513248B (zh) * 2013-09-30 2019-05-24 重庆医药工业研究院有限责任公司 一种托法替尼中间体的纯化方法
MX368464B (es) 2013-12-05 2019-10-02 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
PT2994454T (pt) 2013-12-09 2019-04-02 Unichem Lab Ltd Um processo melhorado para a preparacao de (3r,4r)-(1-benzil-4- metilpiperidin-3-il)-metilamina
US9260438B2 (en) 2014-02-06 2016-02-16 Apotex Inc. Solid forms of tofacitinib salts
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
EP3248980B1 (en) * 2015-01-20 2023-09-06 Wuxi Fortune Pharmaceutical Co., Ltd Jak inhibitor
US10479763B2 (en) 2015-02-17 2019-11-19 Amorepacific Corporation Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives
CN104761556B (zh) * 2015-03-21 2017-06-23 河北国龙制药有限公司 托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
EP3078665A1 (en) 2015-04-10 2016-10-12 OLON S.p.A. Efficient method for the preparation of tofacitinib citrate
EP3290418B1 (en) 2015-04-29 2019-05-15 Wuxi Fortune Pharmaceutical Co., Ltd Janus kinase (jak) inhibitors
JP6761815B2 (ja) 2015-05-01 2020-09-30 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、ピロロ［２，３−ｂ］ピリジニルアクリルアミド、およびそのエポキシド
UA118822C2 (uk) 2015-05-29 2019-03-11 Вуксі Фортуне Фармасьютікал Ко., Лтд Інгібітор янус-кінази
WO2017017542A1 (en) * 2015-07-27 2017-02-02 Unichem Laboratories Limited Tofacitinib orally disintegrating tablets
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
WO2017091681A1 (en) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Selective kinase inhibitors
CN105348287A (zh) * 2015-11-30 2016-02-24 宁波立华制药有限公司 一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
US20190083609A1 (en) 2016-01-18 2019-03-21 Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh) Tofacitinib as vaccination immune modulator
MY191110A (en) 2016-06-30 2022-05-30 Daewoong Pharmaceutical Co Ltd Pyrazolopyrimidine derivatives as kinase inhibitor
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko) 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CN111527091B (zh) 2017-12-28 2023-03-28 株式会社大熊制药 作为激酶抑制剂的氧基-氟哌啶衍生物
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
MA51771B1 (fr) 2018-01-30 2022-03-31 Incyte Corp Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
KR102794603B1 (ko) * 2018-01-31 2025-04-10 티더블유아이 바이오테크놀로지 인코포레이티드 토파시티닙을 포함하는 국소 제형
KR20210018203A (ko) 2018-03-30 2021-02-17 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
KR102131107B1 (ko) * 2019-01-15 2020-07-07 주식회사 다산제약 3-아미노-피페리딘 화합물의 신규한 제조 방법
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
GB2596942B (en) 2019-02-27 2023-05-10 Samson Clinical Pty Ltd Tofacitinib via oral mucosa for use in treatment of autoimmune hair loss or excessing hair shedding
US12269830B2 (en) 2019-03-13 2025-04-08 Intas Pharmaceuticals Ltd. Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
EP3946606B1 (en) 2019-03-27 2025-01-01 Insilico Medicine IP Limited Bicyclic jak inhibitors and uses thereof
WO2020204647A1 (en) * 2019-04-05 2020-10-08 Yuhan Corporation Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same
EP4057989A1 (en) 2019-11-14 2022-09-21 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
JP7371253B2 (ja) 2019-11-25 2023-10-30 デウン ファーマシューティカル カンパニー リミテッド 新規なトリアゾロピリジン誘導体およびこれを含む薬学組成物
EP4125900A1 (en) 2020-04-04 2023-02-08 Pfizer Inc. Methods of treating coronavirus disease 2019
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4308568A1 (en) * 2021-03-15 2024-01-24 Chiesi Farmaceutici S.p.A. Heterocyclic derivatives as janus kinase inhibitors
CN113549075B (zh) * 2021-06-23 2025-09-23 合肥华方医药科技有限公司 一种枸橼酸托法替布非对映异构体杂质的合成方法
EP4180042A1 (en) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising micronized tofacitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8403224A (nl) * 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ATE159257T1 (de) 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
JPH07330732A (ja) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd 光学活性な３−アミノ−１−ベンジルピペリジン誘導体
US6136596A (en) * 1995-05-19 2000-10-24 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
DK0831829T3 (da) 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
MX9800136A (es) 1995-07-05 1998-03-29 Du Pont Pirimidinonas fungicidas.
TR199800012T1 (xx) 1995-07-06 1998-04-21 Novartis Ag Piroloprimidinler ve preparasyon i�in tatbikler.
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
PL321296A1 (en) 1995-11-14 1997-12-08 Pharmacia & Upjohn Spa Derivatives of aryl and heteroaryl purine
US6140317A (en) 1996-01-23 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ATE231148T1 (de) 1996-07-13 2003-02-15 Glaxo Group Ltd Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
DK0938486T3 (da) * 1996-08-23 2008-07-07 Novartis Ag Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US6413971B1 (en) 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
EP0972197A1 (en) * 1997-03-24 2000-01-19 PHARMACIA & UPJOHN COMPANY Method for identifying inhibitors of jak2/cytokine receptor binding
AU3378799A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted pyrrolo(2,3-b)pyridine and pyrrolo(2,3-d)pyrimidine derivatives: modulators of crf1 receptors
HUP0102793A3 (en) 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
CZ20004727A3 (cs) 1998-06-19 2002-03-13 Pfizer Products Inc. Deriváty pyrrolo[2,3-d] pyrimidinu
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU4851599A (en) 1998-06-30 2000-01-17 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
IL141434A0 (en) 1998-08-21 2002-03-10 Parker Hughes Inst Quinazoline derivatives
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
EE05351B1 (et) * 1999-12-10 2010-10-15 Pfizer Products Inc. Prrolo[2,3-d]primidiinhendid
ATE323704T1 (de) * 2000-06-26 2006-05-15 Pfizer Prod Inc Pyrrolo¬2,3-däpyrimidin verbindungen als immunosuppressive wirkstoffe
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
CA2572314A1 (en) * 2004-06-29 2006-01-12 Christopher N. Farthing Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity

Also Published As

Publication number Publication date
DK1666481T3 (da) 2012-10-15
KR20080002931A (ko) 2008-01-04
NZ540332A (en) 2007-05-31
GT200200100AA (es) 2007-07-06
CZ20033260A3 (en) 2004-03-17
NO328578B1 (no) 2010-03-22
PL367945A1 (en) 2005-03-07
NZ530380A (en) 2005-08-26
HUP0400152A3 (en) 2012-12-28
AR037321A1 (es) 2004-11-03
AU2008203170A1 (en) 2008-08-07
ATE519741T1 (de) 2011-08-15
RS52144B (en) 2012-08-31
EP1666481A3 (en) 2006-11-29
EA007251B1 (ru) 2006-08-25
EA200600575A1 (ru) 2006-08-25
IS3023B (is) 2020-08-15
ZA200307982B (en) 2004-10-14
KR20060014459A (ko) 2006-02-15
JP4381137B2 (ja) 2009-12-09
HRP20030943B1 (hr) 2011-11-30
FR17C1031I1 (fr) 2017-10-13
BE2017C032I2 (cs) 2021-07-19
ES2393385T3 (es) 2012-12-20
IL158588A0 (en) 2004-05-12
CN1729192A (zh) 2006-02-01
JP2004534047A (ja) 2004-11-11
SI1666481T1 (sl) 2012-11-30
KR20040003037A (ko) 2004-01-07
HUS1900008I1 (hu) 2020-02-28
GT200200100A (es) 2003-02-11
SK14652003A3 (sk) 2004-05-04
MXPA03011062A (es) 2004-03-19
EP1392694A1 (en) 2004-03-03
EP1666481B1 (en) 2012-09-19
AP2002002550A0 (en) 2002-06-30
AR045680A2 (es) 2005-11-09
US20040229923A1 (en) 2004-11-18
CZ304366B6 (cs) 2014-04-02
KR100869409B1 (ko) 2008-11-21
CR10177A (es) 2008-08-19
MA27029A1 (fr) 2004-12-20
EP1666481A2 (en) 2006-06-07
LUC00031I1 (cs) 2017-08-10
PL228155B1 (pl) 2018-02-28
LTPA2017025I1 (lt) 2017-09-11
OA12612A (en) 2006-06-09
ECSP034865A (es) 2004-01-28
NL300887I2 (nl) 2017-08-31
UA80093C2 (uk) 2007-08-27
GEP20063784B (en) 2006-04-10
CL2008000762A1 (es) 2008-07-04
CY2017028I2 (el) 2018-02-14
FR17C1031I2 (fr) 2018-11-02
EA200301193A1 (ru) 2004-04-29
KR100926875B1 (ko) 2009-11-16
UY27317A1 (es) 2003-02-28
US7301023B2 (en) 2007-11-27
BG66489B1 (bg) 2015-05-29
HU230876B1 (hu) 2018-11-29
EA012666B1 (ru) 2009-12-30
KR20060133117A (ko) 2006-12-22
TW200413370A (en) 2004-08-01
AU2002304401B2 (en) 2008-04-17
CA2448281A1 (en) 2002-12-05
CY1113322T1 (el) 2016-06-22
CU23337B7 (es) 2009-01-20
KR100868814B1 (ko) 2008-11-14
AU2008203170B2 (en) 2009-06-18
LTC1666481I2 (lt) 2018-06-25
PE20030561A1 (es) 2003-06-23
CA2448281C (en) 2009-05-05
ES2369226T3 (es) 2011-11-28
WO2002096909A1 (en) 2002-12-05
PA8546301A1 (es) 2003-05-14
PL409305A1 (pl) 2014-12-22
YU92303A (sh) 2006-08-17
EP1666481B9 (en) 2013-05-01
TWI316061B (en) 2009-10-21
US7432370B2 (en) 2008-10-07
NO20035201L (no) 2003-11-24
BG108389A (bg) 2005-01-31
CY2017028I1 (el) 2018-02-14
US20030073719A1 (en) 2003-04-17
KR20080083028A (ko) 2008-09-12
PT1666481E (pt) 2012-12-03
NO20035201D0 (no) 2003-11-24
IS6993A (is) 2003-10-13
EE200300594A (et) 2004-04-15
NO20093135L (no) 2003-11-24
TWI310384B (en) 2009-06-01
EP1609781B1 (en) 2011-08-10
BR0209246A (pt) 2004-06-15
EP1609781A1 (en) 2005-12-28
MY129649A (en) 2007-04-30
AP1859A (en) 2008-07-02
AU2002304401C1 (en) 2009-03-05
SK288192B6 (sk) 2014-06-03
SK288199B6 (sk) 2014-06-03
NO2017047I1 (no) 2017-09-08
TNSN03128A1 (fr) 2005-12-23
LUC00031I2 (cs) 2017-10-11
HRP20030943A2 (en) 2005-08-31
HUP0400152A2 (en) 2007-07-30

Similar Documents

Publication Publication Date Title
EE05332B1 (et) 3-{(3R,4R)-4-metl-3-[metl(7H-prrolo[2,3-d]primidiin-4-l)amino]piperidiin-1 -l}-3-oksopropionitriil, selle farmatseutiliselt vastuv?etav sool ja nende kasutamine
DK1235830T3 (da) Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
EE200200711A (et) Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
NO20021694L (no) Pyrazolo[4,3-d]pyrimidinderivater
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
AU2001260455A1 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
DE60206946D1 (de) Substituierte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)onderivate gegen neurodegenerative erkrankungen
NO20020931D0 (no) Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger
DE60103909D1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
DE50001191D1 (de) Pyrazolo[4, 3-d]pyrimidine
JP2004501921A5 (cs)
PL361890A1 (en) Use of pyrazolo[4,3-d]pyrimidines
AU2002349013A1 (en) Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases
AU2003256209A1 (en) Use of human protein kinase c-eta in methods for identification of pharmaceutically useful agents
GB2370039B (en) Producing protein arrays and fusion protein for use therein
IL203601A (en) 6-Hello-7-History (optionally converted amino) -Pyrazolo [15, - a] pyrimidine and its use in drug preparation
HU0402095D0 (en) Bicyclic amino acids as pharmaceutically active ingredients
PL337788A1 (en) Method of obtaining 1-{[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazole[3,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl}-4-methylpiperazine
HK1057338A (en) Pyrrolo [2,3-d] pyrimidine nucleoside analogs
AU2002226519A1 (en) Pyrrolo(2,3-d)pyrimidine and their use as purinergic receptor antagonists

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
AA1Y Spc filed

Free format text: PRODUCT NAME: TOFATSITINIIB;REG NO/DATE: EU/1/17/1178 24.03.2017

Spc suppl protection certif: C20170029

Filing date: 20170830

FG1Y Spc granted

Free format text: PRODUCT NAME: TOFATSITINIIB;REG NO/DATE: EU/1/17/1178 24.03.2017

Spc suppl protection certif: C20170029 00347

Filing date: 20170830

Extension date: 20270529